Augmedix, Inc. (AUGX)

Augmedix provided automated medical documentation and data services for hospitals and physician practices. Its products used ambient listening and artificial intelligence, combined with remote medical documentation specialists, to turn conversations between doctors and patients into clinical notes. The goal was to reduce the time physicians spent on electronic health records. The company offered both fully automated and human-assisted versions of its service.

Augmedix was founded in 2012 and was based in San Francisco. It initially drew attention for using smart glasses to capture patient visits for remote scribes. The company became public through a reverse merger and traded over the counter before listing on Nasdaq in 2021 under the symbol AUGX. Large health systems such as HCA Healthcare became important customers and partners.

As generative AI tools for clinical documentation advanced rapidly, competition from much larger companies intensified. Augmedix launched new AI-driven products for emergency departments and outpatient care but remained unprofitable. In July 2024 it agreed to be acquired by Commure, a privately held healthcare technology company backed by General Catalyst.

Under the agreement, Augmedix shareholders received $2.35 per share in cash, valuing the company at about $139 million. The acquisition closed in October 2024 after shareholder and regulatory approvals, and the stock was delisted from Nasdaq. Augmedix's technology was folded into Commure's ambient AI and provider software offerings.